CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
免疫治疗相关毒性的管理，Version 1.2022，NCCN 肿瘤学临床实践指南
英文原题：Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology.
查看英文原题
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
NCCN免疫治疗相关毒性管理指南的目的是为癌症免疫治疗引起的免疫相关不良事件的管理提供指导。NCCN免疫治疗相关毒性管理专家组是一个跨学科小组，由来自NCCN成员机构的代表组成，包括在广泛疾病领域具有专业知识的医学和血液肿瘤学家，以及来自皮肤科、胃肠科、内分泌科、神经肿瘤科、肾脏科、心脏肿瘤科、眼科、肺医学和肿瘤护理领域的专家。本期内容为CAR-T 细胞治疗相关毒性管理建议的摘录及现有证据的回顾。有关NCCN指南的完整版本，包括免疫检查点抑制剂相关毒性管理建议，请访问NCCN.org。
展开英文摘要原文
The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to provide guidance on the management of immune-related adverse events resulting from cancer immunotherapy. The NCCN Management of Immunotherapy-Related Toxicities Panel is an interdisciplinary group of representatives from NCCN Member Institutions, consisting of medical and hematologic oncologists with expertise across a wide range of disease sites, and experts from the areas of dermatology, gastroenterology, endocrinology, neurooncology, nephrology, cardio-oncology, ophthalmology, pulmonary medicine, and oncology nursing.
The content featured in this issue is an excerpt of the recommendations for managing toxicities related to CAR T-cell therapies and a review of existing evidence. For the full version of the NCCN Guidelines, including recommendations for managing toxicities related to immune checkpoint inhibitors, visit NCCN. org.
论文信息
- 作者
- Thompson JA、Schneider BJ、Brahmer J、Achufusi A、Armand P、Berkenstock MK、Bhatia S、Budde LE
- 第一作者单位
- Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance.United States
- 通讯作者单位
- National Comprehensive Cancer Network.
- 文献类型
- 综述
- 期刊
- Journal of the National Comprehensive Cancer Network : JNCCN2022 Apr
- 原文标识
- PubMed 35390769 · DOI 10.6004/jnccn.2022.0020